11,692 Shares in Teva Pharmaceutical Industries Limited (TEVA) Acquired by Conservest Capital Advisors Inc.

Conservest Capital Advisors Inc. acquired a new position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,692 shares of the company’s stock, valued at approximately $375,000.

A number of other institutional investors have also modified their holdings of TEVA. Cribstone Capital Management LLC raised its stake in Teva Pharmaceutical Industries Limited by 3.3% in the first quarter. Cribstone Capital Management LLC now owns 3,141 shares of the company’s stock worth $101,000 after buying an additional 100 shares during the last quarter. Financial Architects Inc raised its stake in shares of Teva Pharmaceutical Industries Limited by 2.3% in the first quarter. Financial Architects Inc now owns 4,443 shares of the company’s stock valued at $143,000 after buying an additional 100 shares in the last quarter. Advisory Services Network LLC purchased a new stake in shares of Teva Pharmaceutical Industries Limited during the first quarter valued at about $163,000. Elite Wealth Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries Limited during the third quarter valued at about $166,000. Finally, CKW Financial Group purchased a new stake in shares of Teva Pharmaceutical Industries Limited during the third quarter valued at about $168,000. 56.34% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded up 1.61% on Friday, reaching $30.92. 6,067,544 shares of the company were exchanged. The firm has a market capitalization of $31.41 billion, a PE ratio of 396.41 and a beta of 0.49. Teva Pharmaceutical Industries Limited has a 12-month low of $27.60 and a 12-month high of $56.44. The company’s 50 day moving average is $30.19 and its 200 day moving average is $33.22. Teva Pharmaceutical Industries Limited also was the target of unusually large options trading activity on Thursday. Investors bought 2,342 call options on the stock. This is an increase of approximately 232% compared to the typical daily volume of 705 call options.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings data on Thursday, May 11th. The company reported $1.06 EPS for the quarter, hitting the consensus estimate of $1.06. The business had revenue of $5.63 billion for the quarter, compared to analyst estimates of $5.69 billion. Teva Pharmaceutical Industries Limited had a net margin of 1.49% and a return on equity of 16.38%. The company’s revenue for the quarter was up 17.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.20 earnings per share. Analysts forecast that Teva Pharmaceutical Industries Limited will post $4.79 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 22nd. Shareholders of record on Monday, June 5th will be given a $0.34 dividend. This represents a $1.36 annualized dividend and a yield of 4.40%. The ex-dividend date is Thursday, June 1st. Teva Pharmaceutical Industries Limited’s dividend payout ratio is 5,802.90%.

ILLEGAL ACTIVITY WARNING: This article was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://transcriptdaily.com/2017/06/17/conservest-capital-advisors-inc-acquires-new-position-in-teva-pharmaceutical-industries-ltd-teva-updated-updated.html.

Several research firms have commented on TEVA. Royal Bank Of Canada reissued an “outperform” rating and set a $38.00 target price (down from $42.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Monday, May 15th. Mizuho lowered their price target on Teva Pharmaceutical Industries Limited from $29.00 to $25.00 and set an “underperform” rating on the stock in a research report on Thursday, May 25th. Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $42.00 price target on shares of Teva Pharmaceutical Industries Limited in a research report on Friday, February 24th. Zacks Investment Research raised Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating in a research report on Monday, April 17th. Finally, Vetr raised Teva Pharmaceutical Industries Limited from a “buy” rating to a “strong-buy” rating and set a $34.25 target price on the stock in a research report on Wednesday, May 17th. One research analyst has rated the stock with a sell rating, sixteen have given a hold rating and fourteen have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $43.56.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply